ROIV Stock Overview
A commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Roivant Sciences Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.84 |
| 52 Week High | US$13.06 |
| 52 Week Low | US$8.73 |
| Beta | 1.23 |
| 1 Month Change | 6.80% |
| 3 Month Change | 1.50% |
| 1 Year Change | -4.66% |
| 3 Year Change | 196.99% |
| 5 Year Change | n/a |
| Change since IPO | 4.23% |
Recent News & Updates
Recent updates
Roivant Sciences: Primed For Growth With A De-Risked Pipeline
Apr 23Industry Analysts Just Upgraded Their Roivant Sciences Ltd. (NASDAQ:ROIV) Revenue Forecasts By 21%
Feb 12
Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade)
Feb 05
Late-stage Trials For Brepocitinib And Batoclimab Will Unlock Potential, But Execution Risks Remain
Successful clinical trials and strategic deals may improve revenue and net margins by focusing on high-value areas.Roivant Sciences: A Biotech Growth Play With Major Ambitions
Dec 04Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility
Oct 22Statutory Earnings May Not Be The Best Way To Understand Roivant Sciences' (NASDAQ:ROIV) True Position
Aug 22Roivant Sciences: Inherently Risky Business Model, But Track Record Impresses
Aug 22Roivant Sciences: Executing On Huge Buyback Program With More To Come
Jun 02Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success
Mar 18Shareholder Returns
| ROIV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.4% | 0.8% | 1.6% |
| 1Y | -4.7% | -13.8% | 11.7% |
Return vs Industry: ROIV exceeded the US Biotechs industry which returned -14.7% over the past year.
Return vs Market: ROIV underperformed the US Market which returned 11.9% over the past year.
Price Volatility
| ROIV volatility | |
|---|---|
| ROIV Average Weekly Movement | 5.4% |
| Biotechs Industry Average Movement | 12.0% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: ROIV has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ROIV's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 908 | Matt Gline | roivant.com |
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases.
Roivant Sciences Ltd. Fundamentals Summary
| ROIV fundamental statistics | |
|---|---|
| Market cap | US$7.70b |
| Earnings (TTM) | -US$717.26m |
| Revenue (TTM) | US$122.59m |
Is ROIV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ROIV income statement (TTM) | |
|---|---|
| Revenue | US$122.59m |
| Cost of Revenue | US$592.12m |
| Gross Profit | -US$469.53m |
| Other Expenses | US$247.73m |
| Earnings | -US$717.26m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 29, 2025
| Earnings per share (EPS) | -1.01 |
| Gross Margin | -383.03% |
| Net Profit Margin | -585.11% |
| Debt/Equity Ratio | 0% |
How did ROIV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 12:10 |
| End of Day Share Price | 2025/05/19 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Roivant Sciences Ltd. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chi Meng Fong | BofA Global Research |
| Louise Chen | Cantor Fitzgerald & Co. |
| Neena Bitritto-Garg | Citigroup Inc |